Topics in this section

Hepatitis and HIV: latest news

Hepatitis and HIV resources

Hepatitis and HIV features

Hepatitis and HIV in your own words

Hepatitis and HIV news from aidsmap

More news

Hepatitis and HIV news selected from other sources

  • New HCV drugs pass muster in real world

    Clinical trials for some of the new direct-acting agents against hepatitis C (HCV) have yielded some impressive efficacy numbers. But how well do the drugs stack up in the real world?

    11 November 2014 | MedPage Today
  • New pill that can cure hepatitis C approved for patients in Scotland

    Daclatasvir is an oral once-daily pill, used in combination with other medicinal products, to treat adult patients with chronic hepatitis C. The decision makes Scotland the first country in Europe to adopt positive guidance for daclatasvir and means it will be routinely available to eligible patients through the Scottish NHS.

    11 November 2014 | STV
  • Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

    “Unfortunately, history seems to be repeating itself with BMS, who hasn’t learned from the company’s poor track record responding to the HIV epidemic,” says Rohit Malpani of Doctors Without Borders.

    05 November 2014 | Wall Street Journal
  • Half of people with hepatitis C unaware

    Dr Vivian Hope of Public Health England said: "With around half of those people living with hepatitis C still unaware of their infection, we need to do more to increase diagnosis rates. Ultimately, this will help reduce the current high level of infection we’re still seeing among people who inject drugs."

    05 November 2014 | Public Health England press release
  • Coffee, Even Decaf, May Promote Liver Health

    Drinking coffee, whether decaffeinated or regular, is linked to healthier levels on tests indicating liver function.

    16 October 2014 | AIDSMeds
  • IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

    AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.

    16 October 2014 | HIVandHepatitis.com
  • Investigating an outbreak of hepatitis C virus among MSM without HIV

    Given the reports about the high-risk practices taking place in London (and likely other cities in high-income countries), it is likely that cases of sexually transmitted HCV are also occurring in some HIV-negative MSM. To investigate this possibility, researchers in London reviewed health-related information collected from HIV-negative patients who sought care at selected clinics in that city.

    01 October 2014 | CATIE
  • Study Dampens HOPE of HIV Organ Donations

    The HIV Organ Policy Equity (HOPE) Act, which legalizes research into organ tranplants from HIV-positive donors to HIV-positive recipients, is less than a year old, but a new study already suggests the organs may be of poor quality.

    17 September 2014 | Medscape (requires registration)
  • Uncovering cases of early HCV infection in HIV-positive men

    While screening the blood samples of patients for HCV antibodies can be useful, a new study suggests that in some cases such antibodies may not appear for several months after HCV infection has occurred. In such cases, acute HCV infection might be missed if antibody tests alone are used for screening - RNA testing should be used to screen HCV infection.

    17 September 2014 | CATIE
  • US: HIV medical organizations challenge insurer restrictions to HCV treatment

    The American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA), the two largest professional associations representing HIV clinicians in the U.S., are challenging new health plan cost control policies barring many qualified HIV care providers from prescribing certain medications that treat hepatitis C (HCV).

    04 September 2014 | EATG / AAHIVM / HIVMA
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also